Recombinant Human HLA-A*02:06&B2M Monomer Protein (HEK293)，Avi & His

The HLA-A*02:06 and β2-microglobulin (B2M) monomer recombinant protein represents a significant focus in immunological research due to its role in antigen presentation and immune response. Human leukocyte antigen (HLA) molecules are vital for the recognition of foreign peptides by T cells, and HLA-A*02:06 is one of the most prevalent class I alleles in the population, associated with various diseases, including autoimmunity and cancer. The binding of peptides to HLA molecules is critical for the activation of cytotoxic T lymphocytes, which can target and destroy infected or malignant cells. The importance of B2M lies in its stabilization of the HLA-A molecule on the cell surface, allowing for effective immunological functions. Studying the HLA-A*02:06/B2M complex can provide insights into the mechanisms of T cell activation, the design of T cell-based therapies, and the development of vaccines. Through recombinant technology, researchers can produce this monomeric protein in a controlled environment, enabling detailed structural and functional analyses. Understanding the interactions between HLA-A*02:06 and its peptide ligands, as well as its role in immune evasion by tumors, could pave the way for novel therapeutic strategies aimed at enhancing anti-tumor immunity and improving clinical outcomes in cancer treatment. Furthermore, the availability of this recombinant protein contributes to the development of assays for peptide-HLA binding studies, facilitating advancements in personalized medicine and immunotherapy. Overall, the research surrounding HLA-A*02:06 and B2M monomer recombinant proteins is crucial in the broader context of immune system modulation and therapeutic interventions.